Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company ArQule has reported that symptomatic and asymptomatic QTc prolongation has been observed in a Phase I dose escalation trial with ARQ 171, a second generation product in its E2F-1 cancer therapy program.
Subscribe to our email newsletter
These observations were made based on EKGs from patients who received doses of ARQ 171 from 380 to 760 milligrams per meter squared.
QTc prolongation is a disorder that can result in an irregular heartbeat and is associated with increased risk of sudden cardiac death.
The company is currently reviewing EKGs from patients previously treated at lower doses. Upon completion of this review, the company will make a further decision about continuing this dose escalation trial. The company expects the analysis of QTc prolongation data to be complete between the end of 2007 and early 2008.